145 results about "Premature atherosclerosis" patented technology

The present invention identifies two circulating proteins that have been newly identified as being differentially expressed in atherosclerosis. Circulating levels of these two proteins, particularly as a panel of proteins, can discriminate patients with acute myocardial infarction from those with stable exertional angina and from those with no history of atherosclerotic cardiovascular disease. Such levels can also predict cardiovascular events, determine the effectiveness of therapy, stage disease, and the like. For example, these markers are useful as surrogate biomarkers of clinical events needed for development of vascular specific pharmaceutical agents.

Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.

This invention provides novel peptides that ameliorate one or more symptoms of atherosclerosis. The peptides are highly stable and readily administered via an oral route.

An apparatus for ablating deposits along the blood vessel of human and animals is disclosed. The apparatus has an extracting and pressurizing unit for extracting blood from a supply vessel and pressurizing it plus a downstream delivering and injecting unit for delivering and injecting the filtered and pressurized source blood into a blood vessel under treatment. Besides inducing a blood circulation and having ablation devices like ultrasound and RF heating, the apparatus ablates the deposits from a nearby portion of the vessel. The characteristics of selective ablation and self-termination make the proposed apparatus safe and effective in treating early-stage atherosclerosis. A DC discharging device can be included to neutralize excess surface charge generation on the wounded healthy tissues following ablation for disinfection and anti-inflammation. Placement of the blood extracting point just downstream of the blood injecting point insures thorough collection and removal of blood-clogging plaque and calcification fragments.

The present invention inter alia provides a method, and use thereof, of diagnosing and / or predicting atherosclerosis or CVD by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in detecting and predicting atherosclerosis and CVD than currently utilized clinical markers. Also provided is an antibody towards said lipids, and the use thereof for predicting, diagnosing, preventing and / or treating atherosclerosis or CVD. The invention additionally relates to kits comprising lipids and / or an antibody thereto, for use in the prediction and / or diagnosis of atherosclerosis or CVD.

The invention provides compounds and pharmaceutical compositions that can be used to treat or prevent atherosclerosis, stroke, and other ischemic vascular diseases, dyslipidemia and hypercholestcrolemia and prevent complications of these conditions. Agents in accordance with the invention include; tauroursodeoxycholic acid (TUDCA), and analogs and derivatives thereof; 4-phenyl butyric acid (PBA), and analogs and derivatives thereof; and trimethyl N-oxide (TMAO), and analogs and derivatives thereof.

This invention involves the new use of a diagnostic test to determine the risk of atherosclerotic diseases such as myocardial infarction and stroke, particularly among individuals with no signs or symptoms of current disease and among nonsmokers. Further, this invention involves the new use of a diagnostic test to assist physicians in determining which individuals at risk will preferentially benefit from certain treatments designed either to prevent first or recurrent myocardial infarctions and strokes, or to treat acute and chronic cardiovascular disorders. Methods for treatment also are described.

The invention provides a method for establishing a machin hyperlipidemia and atherosclerosis model. The method comprises the following steps of (1) preparing a plurality of machin as candidates; (2) detecting four biochemical indexes of the blood of the candidate machin such as TC,TG, HDL-C and LDL-C; (3) selecting the machin for the modeling to be grouped; (4) adding more than one of 5 to 20 percent of yolk powder, 5 to 20 percent of lard oil and 0.5 to 2 percent of cholesterol on the basis of 58 to 89.5 percent of basic feed according to the formula of high-fat feed by weight percent to prepare a plurality of formulas, respectively utilizing one formula to feed one group of machin, and determining an optimal formula according to the variation of the biochemical indexes; (5) completing the establishment of a hyperlipidemia model; and (6) detecting relevant indexes of the model. Through the method for establishing the machin hyperlipidemia and atherosclerosis model, the optimally selected high-fat feed can successfully induce the increase of the blood fat of the machin and is very stable.

The present invention is in the field of prevention and treatment of atherosclerosis and atherosclerosis-related clinical conditions. In particular, the present invention relates to the use of sphingolipids, more preferably phytosphingosine, sphingosine, sphinganine, ceramide, cerebroside lyso-sphingomyelin and / or sphingomyelin for prevention and treatment of inflammatory processes associated with atherosclerosis, psoriasis, colitis or auto-immune diseases in a subject.

Disclosed are methods for inhibiting Ras activity such as cell proliferation associated with vascular injury such as post-angioplasty restenosis and atherosclerosis. Preferred Ras antagonists are S-trans-trans farnesylthiosalicylic acid (FTS) and structurally related compounds (or analogs) thereof.

Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.

An animal model of coronary heart disease has been developed where myocardial infarct can be induced by altering the animal's diet. In all embodiments, this animal model is a result of reduced activity of scavenger receptor class BI (SR-BI) and apolipoprotein E (ApoE). In a preferred embodiment, the model is a result of crossbreeding two transgenic mouse lines: a knockout of SR-BI (SR-BI− / −) and an impaired ApoE expressor (hypoE). The impaired ApoE gene results in only 2-5% expression of ApoE and a reduction in cholesterol homeostasis. Resulting animals are predisposed to hypercholesterolemia but can live longer than a year on a normal low fat diet. Serum plasma levels can be significantly elevated by changing the animal's diet to one containing high levels of fat and cholesterol. Within a month on a high fat, high cholesterol diet, animals develop atherosclerosis and myocardial infarction occurs. Survival depends on the nature of the diet and the conditions of animal husbandry and can typically be around 20-30 days after administration of the modified diet depending on the specific conditions. Housing the animals alone or in groups significantly affects survival of these animals on a high fat diet. Analysis of B- and T-cell deficient SR-BI / ApoE / RAG2 triple knockout mice established that B- and T-lymphocytes do not play a key role in the pathophysiology of the SR-BI ApoE dKO model of human disease. These animal models can be used to study mechanisms and progression of CHD as a function of diet, treatment with drugs to be screened for efficacy or undesirable side effects, and social environmental effects.

A method for in vitro diagnosis of atherosclerosis, comprising: (a) obtaining a sample from a subject; (b) determining expression levels of one or more microRNAs (miRNAs) as atherosclerotic biomarkers and an internal control RNA; (c) computing the relative expression levels of the one or more miRNAs as atherosclerotic biomarkers; (d) computing a prediction model with one or more variables, wherein the variable includes one or more relative expression levels of the one or more miRNAs as atherosclerotic biomarkers and one or more risk factors of atherosclerosis; and (e) computing a prediction probability by the prediction model, wherein the subject is diagnosed with atherosclerosis if the probability is more than 0.5 is presented. A kit for in vitro diagnosis of atherosclerosis or prognosis of atherosclerosis-inducing diseases is also presented.

A method of treating or preventing a subject's health problem that is related to an underlying disorder in the functioning of the metabolic system of the subject includes the step of administering a therapeutically effective dosage of glycine. For health problems associated with the subject's bones, cartilage or connective tissue, including degenerative diseases such as arthrosis and arthritis, injuries due to physical trauma, the condition of one's skin, teeth, gums, finger nails, eyes, ears, vocal chords or muscles, or diseases such as osteoporosis, asthma, multiple sclerosis or atherosclerosis, the administering step involves daily ingesting glycine at a rate in the range of 0.1 to 0.7 g / Kg of the subject's body weight.

The invention provides drugs used for treating atherosclerotic diseases such as carotid artery stenosis, lower extremity atherosclerotic occlusive disease, and coronary heart disease, and more specifically discloses applications of compound Szeto-Schiller-31 (SS-31) in preparing drugs or preparations used for treating atherosclerosis and related diseases, and belongs to the field of medicine, and more specifically belongs to the field of novel pharmaceutical applications of compounds. It is found via experiments that SS-31 is capable of reducing atherosclerosis degree, reducing mouse arterial ROS level obviously, reducing oxidative damage, increasing ATP level, reducing the content of macrophages at atherosclerotic plaques obviously, increasing the content of smooth muscle cells and the content of collagen at atherosclerotic plaques obviously, stabilizing atherosclerotic plaques, improving inflammation level obviously, and reducing expression of lipid intake protein at atherosclerotic plaques; and it is shown by results that SS-31 is capable of treating atherosclerosis and related diseases.

The invention relates to a non-invasive skin free-cholesterol detection device for evaluating the atherosclerosis risk. A palm part of a tester is coated with a specific reagent, the relative content of free cholesterol on the skin of the tester can be acquired by measuring the variation situation of a reaction reagent reflection spectrum by utilizing an optical method, and then the risk for a subject suffering the atherosclerosis disease can be further evaluated.

The invention provides atherosclerotic early-period identification model construction technology based on metagenome sequencing. According to the technology, an international advance Illumina NovaSeqplatform is utilized. Nextera transposon air gun metagenome sequencing technology is applied on the human feces and oral cavity flora metagenome. In cooperation with traditional high-flux sequencing,metagenome data are generated. Furthermore a database and a system are used for performing metagenome sequencing data analysis. Through performing training set and verifier machine rectification on data, and in cooperation with machine learning and a neural network algorithm, a reliable early-period atherosclerotic identification model is generated; and furthermore verification is performed through expanding a metagenome biomarker. The technology is based on relatively large scale of systematical queue researching. Correlation analysis of pathogenesis change and bacterial spectrum is performedthrough the queue, thereby determining an early-period marker, and supplying a systematical researching method with higher value in a preventative medical science field.

The invention relates to the technical field of medicine, and provides new application of macrophage beta-profilin-1, namely application of macrophage beta-profilin-1 to preparation of a drug for preventing or treating atherosclerosis. It is proved through experiments that in comparison with wild type mice, the serum total cholesterol content of macrophage beta-arrestin-1 specificity myelogenous knockout mice is remarkably increased, and it is found through oil red O dyeing that the aorta overall plaque area and the plaque area of aorta roots are obviously increased compared with those of the wild type mice. By changing the macrophage beta-arrestin-1 gene expression level through virus transfection, and it is found that macrophage phagocytosis lipid is increased by interfering beta-arrestin-1 expression and is decreased by overexpressing beta-arrestin-1. The results show that the beta-arrestin-1 gene has a protective effect on the severity degree and prognosis of atherosclerosis.

The invention belongs to the field of traditional Chinese medicines and particularly relates to a traditional Chinese medicine preparation for treating a coronary heart disease with spleen deficiency and turbid phlegm caused by atherosclerosis. The traditional Chinese medicine preparation is prepared from the following components in parts by weight: 30-40g of astragalus membranaceus, 30-40g of codonopsis pilosula, 30-40g of snakegourd fruits, 10-30g of pinellia ternate, 30-40g of rhizoma atractylodis macrocephalae, 30-40g of poria cocos, 30-40g of salviae miltiorrhizae and 5-15g of honey-fried licorice roots. The traditional Chinese medicine is significant in curative effect and high in practical pertinence, and is mainly used for treating heart and chest tightness, shortness of breath caused by excessive phlegm, heaviness of limbs, accompanied abdominal bloating, lassitude and weakness, anorexia and loose stool and cough spit sputum caused by chronic stable angina.

The present invention relates to the identification of lipid oxidising abzymes as a key pathogenic factor in atherosclerotic disorders. Methods and means for the reduction of abzyme mediated lipid oxidation in the vascular system are provided as therapeutic approaches for the treatment of atherosclerotic disorders.

The invention discloses applications of arctigenin on preparing drugs for curing atherosclerosis or myocardial infarction, and belongs to the field of medicine. In the novel medical application disclosed by the invention of arctigenin, the dosage amount of arctigenin is 0.001 to 200 mg / kg for each day, arctigenin can be made into oral preparations, injection preparations, or external preparations, wherein the oral micro-emulsion preparation of arctigenin has the best effect. The arctigenin has the advantages of little by-effect, prominent curing advantage, and high drug compliance of patients, and has a very vast medical application prospect.